Biocon Pharma gets FDA nod for norepinephrine bitartrate injection
Norepinephrine bitartrate injection is indicated to raise blood pressure in adult patients with acute hypotension.
Biocon’s subsidiary Biocon Pharma has received the Food and Drug Administration’s permission for norepinephrine bitartrate injection (4 mg/4 ml, 1 mg/ml) in a single-dose vial, the company said in a stock exchange filing.
Norepinephrine bitartrate injection is a critical drug used to elevate blood pressure in adults experiencing acute hypotension.
Biocon Pharma is now authorized to commercialize the product in the U.S. market.
[Read more: FDA gives Biocon Biologics approval for Stelara biosimilar]
The approval further adds to Biocons portfolio of complex drug products, Biocon said.
[Read more: Biocon Biologics, Civica collaborate to expand insulin Aspart access]